DISCUSSION
TEAEs, hepatitis, cholangiocarcinoma
HEPATITIS, METASTATIC CHOLANGIOCARCINOMA, CHOLANGIOCARCINOMA
In this phase II bridging study of pemigatinib in previously treated Chinese patients with unresectable locally advanced or metastatic cholangiocarcinoma carrying The frequency of Differences in patient characteristics, such as age, ethnicity, proportion of patients with a history of hepatitis, and prior treatments, preclude a direct comparison of results from our study and FIGHT‐202.TEAEs were generally mild in Chinese patients with cholangiocarcinoma receiving pemigatinib. TEAEs of ≥grade 3, leading to dose reduction, dose interruption, and treatment discontinuation occurred in eight (25.8%), one (3.2%), four (12.9%), and zero patients, respectively, as compared with 93 (64%), 20 (14%), 62 (42%), and 13 (9%) in the other patient populations in FIGHT‐202.NGS‐based assays provide comprehensive and precise profiling of genetic alterations, which is valuable for identifying predictive biomarkers and resistance mechanisms. Foundation One CDx has been approved by the US Food and Drug Administration as a companion diagnostic for pemigatinib.Because of the lack of an efficacious second‐line standard of care for cholangiocarcinoma, this phase II study did not include a comparator arm. Another limitation of this study was a sample size of 31 enrolled patients as compared with 107 patients with In conclusion, the encouraging efficacy and favorable safety profile of pemigatinib support its usage as a treatment for Chinese patients with unresectable locally advanced or metastatic cholangiocarcinoma and 